Patents by Inventor Mathieu MAINGOT

Mathieu MAINGOT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RIFABUTIN ANALOGS FOR THE TREATMENT OF DISEASE
    Publication number: 20260098046
    Abstract: The present invention relates to compounds and pharmaceutical compositions comprising the same for the treatment, amelioration and/or prevention of disease. In some embodiments, the disease is a bacterial infection. In some embodiments, the bacterial infection is caused by one or more bacterium belonging to a genus of non-tuberculous Mycobacteria, preferably M. abscessus.
    Type: Application
    Filed: September 29, 2023
    Publication date: April 9, 2026
    Inventors: Kevin ANTRAYGUES, Marilyne BOUROTTE, Glenn E. DALE, Olivier DEFERT, Marc GITZINGER, Sergio LOCIURO, Mathieu MAINGOT, Vincent TREBOSC, Nicolas WILLAND
  • RIFABUTIN ANALOGS FOR THE TREATMENT OF DISEASE
    Publication number: 20250235434
    Abstract: The present invention relates to compounds and pharmaceutical compositions comprising the same for the treatment, amelioration and/or prevention of disease. In some embodiments, the disease is a bacterial infection. In some embodiments, the bacterial infection is caused by one or more bacterium belonging to a genus of non-tuberculous Mycobacteria, preferably M. abscessus.
    Type: Application
    Filed: April 6, 2023
    Publication date: July 24, 2025
    Inventors: Kevin ANTRAYGUES, Marilyne BOUROTTE, Glenn E. DALE, Olivier DEFERT, Marc GITZINGER, Sergio LOCIURO, Mathieu MAINGOT, Vincent TREBOSC, Nicolas WILLAND
  • RIFAMYCIN DERIVATIVES FOR THE TREATMENT OF DISEASES
    Publication number: 20250101039
    Abstract: The present disclosure relates to compounds and pharmaceutical compositions comprising the same for the treatment, amelioration and/or prevention of disease. In some embodiments, the disease is a bacterial infection. In some embodiments the infection is caused by a bacteria belonging to Acinetobacter spp., Clostridium spp., Enterococcus spp., Hemophilus spp., Legionella spp., Mycobacterium spp. (tuberculous and non-tuberculous Mycobacteria), Neisseria spp., Staphylococcus spp., Streptococcus spp., Listeria monocytogenes, Moraxella catarrhalis, Bacillus spp., Bacteroides spp., Gardnerella vaginalis, Lactobacillus spp., Mobiluncus spp., Helicobacter pylori, Campylobacter jejuni, Chlamydia trachomatis and/or Toxoplasma gondii; preferably the bacterial infection is caused by S. aureus, A. baumannii, E. faecium, E. faecalis, S. epidermidis, S. pneumoniae, S. pyogenes, H. influenzae, M. abscessus, M. tuberculosis, and/or M.
    Type: Application
    Filed: January 27, 2023
    Publication date: March 27, 2025
    Inventors: Kevin ANTRAYGUES, Marilyne BOUROTTE, Glenn E. DALE, Olivier DEFERT, Bruna GIOIA, Marc GITZINGER, Sergio LOCIURO, Mathieu MAINGOT, Vincent TREBOSC, Nicolas WILLAND
  • RIFABUTIN ANALOGS FOR THE TREATMENT OF DISEASE
    Publication number: 20250051356
    Abstract: The present disclosure relates to compounds and pharmaceutical compositions comprising the same for the treatment, amelioration and/or prevention of disease. In some embodiments, the disease is a bacterial infection. In some embodiments, the bacterial infection is caused by one or more bacterium belonging to a genus of non-tuberculous Mycobacteria, preferably M. abscessus.
    Type: Application
    Filed: December 21, 2022
    Publication date: February 13, 2025
    Inventors: Kevin ANTRAYGUES, Marilyne BOUROTTE, Glenn E. DALE, Olivier DEFERT, Marc GITZINGER, Sergio LOCIURO, Mathieu MAINGOT, Vincent TREBOSC, Nicolas WILLAND